Having trouble viewing this email? View in your browser.
It was a pleasure to hear from so many international experts on cutting-edge developments in infectious disease. In case you missed us, please see a round-up of some of our key sessions and learnings below.
  During this lively symposium session, our expert faculty drew on their extensive experience and explored several key considerations for the development and implementation of seasonal influenza vaccination programmes.

Natasha Halasa,
MD, MPH
ESCMID-appointed chairperson,
Craig Weaver Professor of Pediatrics,
Vanderbilt University, Nashville, US

Lauren Parker,
PhD
Scientific and Technical Lead,
AstraZeneca, UK

Jaime Jesús Pérez-Martín,
MD, MPH
Senior Technician of Public Health,
Murcia Region, Spain

George Kassianos,
CBE, MD, FRCGP
National Immunisation Lead,
Royal College of General
Practitioners, UK

Key take-home points:
  • Following World Health Organization recommendations, several different vaccine platforms are used to generate seasonal influenza vaccines — a flu vaccine is no longer just a flu vaccine!
  • Children are significantly impacted by influenza and play a role in its transmission throughout society.
  • The UK has demonstrated successful implementation of an extensive paediatric influenza vaccination campaign, demonstrating high vaccine coverage and broad societal public health impact.
  • Recently, Spain has expanded its paediatric vaccination campaign, with the differences and similarities of these approaches showcasing the benefits of national immunisation programmes.
  Rosalind Hollingsworth, PhD
Global Medical Affairs Head,
Vaccines and Immune Therapies,
AstraZeneca, US 		This session examined how a complementary approach to the prevention of infectious diseases with vaccines and monoclonal antibodies can help to build a future for all.
Key take-home points:
  • Vaccination is a leading public health intervention to prevent disease, but is not effective for some populations.
  • New technologies are driving advancements, including virus-like particles and bioconjugate platform technologies.
  • Intelligent design of monoclonal antibodies can offer an alternative for those who do not respond to vaccination.

These sessions were organised and funded by AstraZeneca.

The information displayed during the meeting is exclusively for healthcare professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public.

La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos. Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general.

Vault ID: ES-29673; Date of approval: April 2024.

©2024 AstraZeneca Global UK. 1 Francis Crick Avenue, Cambridge,
Cambridgeshire CB2 0RE, United Kingdom. All rights reserved.

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.